Hormonal
Elevated triglycerides serve as a marker for increased numbers of triglyceride-rich lipoprotein (TRL) remnants, which are directly atherogenic by penetrating the arterial wall, accumulating in plaques, and promoting inflammation and thrombosis.
High triglycerides are not just a number; they represent particles that can physically enter artery walls and cause inflammation. Keeping triglycerides low (below 150 mg/dL) helps prevent these particles from building up in your arteries.
These data are compatible with the view that it is the number of TRL and remnant particles that cause CVD... TRL remnants can contribute either directly to plaque formation following penetration of the arterial wall... or potentially indirectly following liberation of lipolytic products... which may activate pro-inflammatory signalling pathways.
Why this rating
Supported by mechanistic studies, animal models, and epidemiological data linking TRL remnants to plaque formation.
Source
Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management
M. John Chapman et al. · European Heart Journal · 2011
DOI 10.1093/eurheartj/ehr112
More from this paper
- In patients at high cardiovascular risk who have achieved LDL-C goals, elevated triglycerides (≥1.7 mmol/L) and/or low HDL-C (<1.0 mmol/L) remain independent predictors of cardiovascular events, and therapeutic targeting of these markers provides incremental risk reduction.Good
- Low HDL-C is associated with increased cardiovascular risk independent of LDL-C levels, and therapeutic strategies to raise HDL-C (e.g., niacin, fibrates) may provide benefit, although genetic evidence for HDL-C as a causal factor is less clear than for TRL remnants.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →